Antiepileptic Drugs: The Old and the New

Emergency Medicine Clinics of North America

Volumn 29, Issue 1, 2011, Pages 141-150

  Hung, Oliver L ^a   Shih, Richard D ^a  

^a MORRISTOWN MEMORIAL HOSPITAL   (United States)

Author keywords

Antiepileptic drugs; Benzodiazepine; Overdose; Seizure

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ANTICONVULSIVE AGENT; CALCIUM CHANNEL; CARBAMAZEPINE; CARBONATE DEHYDRATASE INHIBITOR; CLONAZEPAM; CORTICOSTEROID; CYCLOSPORIN; DIGOXIN; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; FOSPHENYTOIN SODIUM; GABAPENTIN; GLUTAMATE RECEPTOR; LAMOTRIGINE; MEPROBAMATE; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PHENOBARBITAL; PHENOTHIAZINE; PHENYTOIN; SODIUM CHANNEL; TIAGABINE; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; VOLTAGE DEPENDENT SODIUM CHANNEL; WARFARIN; ZONISAMIDE;

ABDOMINAL PAIN; ABSENCE; ACNE; ACUTE KIDNEY FAILURE; ACUTE PANCREATITIS; ACUTE PSYCHOSIS; AGITATION; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; APLASTIC ANEMIA; APPLICATION SITE REACTION; ATAXIA; BRADYCARDIA; BRAIN DEATH; BRAIN EDEMA; CENTRAL NERVOUS SYSTEM DEPRESSION; CENTRAL NERVOUS SYSTEM DISEASE; CLOSED ANGLE GLAUCOMA; COMA; COMPLEX PARTIAL SEIZURE; CONTINUOUS INFUSION; CRYSTALLURIA; DIPLOPIA; DISRUPTIVE BEHAVIOR; DIZZINESS; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG OVERDOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSARTHRIA; EPILEPTIC STATE; ERYTHEMA; ERYTHEMA MULTIFORME; FACE DEFORMITY; FACIAL COARSENING; FATIGUE; FOCAL EPILEPSY; GABAERGIC TRANSMISSION; GASTROINTESTINAL TOXICITY; GINGIVA HYPERPLASIA; GRAND MAL SEIZURE; HEART ARREST; HEART ARRHYTHMIA; HEMATURIA; HIRSUTISM; HUMAN; HYPERACTIVITY; HYPERAMMONEMIA; HYPERTHERMIA; HYPONATREMIA; HYPOTENSION; IDIOSYNCRATIC HEPATOXICITY; INFUSION SITE REACTION; LENNOX GASTAUT SYNDROME; LETHARGY; LEUKOPENIA; LIVER DISEASE; LIVER TOXICITY; LOADING DRUG DOSE; MACULOPAPULAR RASH; MEASLES LIKE RASH; METABOLIC ACIDOSIS; MOOD DISORDER; MYOCLONUS SEIZURE; NAUSEA; NEPHROLITHIASIS; NERVE CELL MEMBRANE STEADY POTENTIAL; NEUROPATHIC PAIN; NEUROTOXICITY; NYSTAGMUS; PATIENT COMPLIANCE; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; PURPURA; RESPIRATION DEPRESSION; RESTLESSNESS; REVIEW; REYE LIKE SYNDROME; SEDATION; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SPASTICITY; STEVENS JOHNSON SYNDROME; SUICIDE ATTEMPT; SWEATING; TACHYCARDIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TINNITUS; TONIC CLONIC SEIZURE; TOXIC EPIDERMAL NECROLYSIS; TOXIC HEPATITIS; TREMOR; VESICULAR RASH; VOMITING; WEIGHT GAIN;

EID: 78649426707     PISSN: 07338627     EISSN: 07338627     Source Type: Journal    
DOI: 10.1016/j.emc.2010.09.004     Document Type: Review

References (37)

1. Kramlinger K.G., Phillips K.A., Post R.M. Rash complicating carbamazepine treatment. J Clin Psychopharmacol 1994, 14(6):408-413.
2. Cohen H., Howland M.A., Luciano D.J., et al. Feasibility and pharmacokinetics of carbamazepine oral loading doses. Am J Health Syst Pharm 1998, 55(11):1134-1140.
3. Donovan P.J., Cline D. Phenytoin administration by constant intravenous infusion: selective rates of administration. Ann Emerg Med 1991, 20(2):139-142.
4. Earnest M.P., Marx J.A., Drury L.R. Complications of intravenous phenytoin for acute treatment of seizures. Recommendations for usage. JAMA 1983, 249(6):762-765.
5. Cranford R.E., Leppik I.E., Patrick B., et al. Intravenous phenytoin in acute treatment of seizures. Neurology 1979, 29(11):1474-1479.
6. Osborn H.H., Zisfein J., Sparano R. Single-dose oral phenytoin loading. Ann Emerg Med 1987, 16(4):407-412.
7. Ratanakorn D., Kaojarern S., Phuapradit P., et al. Single oral loading dose of phenytoin: a pharmacokinetics study. J Neurol Sci 1997, 147(1):89-92.
8. Fischer J.H., Patel T.V., Fischer P.A. Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures. Clin Pharmacokinet 2003, 42(1):33-58.
9. Powell-Jackson P.R., Tredger J.M., Williams R. Hepatotoxicity to sodium valproate: a review. Gut 1984, 25(6):673-681.
10. Raskind J.Y., El Chaar G.M. The role of carnitine supplementation during valproic acid therapy. Ann Pharmacother 2000, 34(5):630-638.
11. Hovinga C.A., Chicella M.F., Rose D.F., et al. Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus. Ann Pharmacother 1999, 33(5):579-584.
12. Limdi N.A., Faught E. The safety of rapid valproic acid infusion. Epilepsia 2000, 41(10):1342-1345.
13. Sinha S., Naritoku D.K. Intravenous valproate is well tolerated in unstable patients with status epilepticus. Neurology 2000, 55(5):722-724.
14. Kleckner N.W., Glazewski J.C., Chen C.C., et al. Subtype-selective antagonism of N-methyl-D-aspartate receptors by felbamate: insights into the mechanism of action. J Pharmacol Exp Ther 1999, 289(2):886-894.
15. Kaufman D.W., Kelly J.P., Anderson T., et al. Evaluation of case reports of aplastic anemia among patients treated with felbamate. Epilepsia 1997, 38(12):1265-1269.
16. Ben-Menachem E. Expanding antiepileptic drug options: clinical efficacy of new therapeutic agents. Epilepsia 1996, 37(Suppl 2):S4-S7.
17. Hwang T.L., Still C.N., Jones J.E. Reversible downbeat nystagmus and ataxia in felbamate intoxication. Neurology 1995, 45(4):846.
18. Nagel T.R., Schunk J.E. Felbamate overdose: a case report and discussion of a new antiepileptic drug. Pediatr Emerg Care 1995, 11(6):369-371.
19. Rengstorff D.S., Milstone A.P., Seger D.L., et al. Felbamate overdose complicated by massive crystalluria and acute renal failure. J Toxicol Clin Toxicol 2000, 38(6):667-669.
20. Meier K.H., Olson K.R., Olson J.L. Acute felbamate overdose with crystalluria. Clin Toxicol 2005, 43:189-192.
21. Neurontin, gabapentin [package insert]. Neurontin Parke-Davis, New York (NY); 2010.
22. Pittenger C., Desan P.H. Gabapentin abuse, and delirium tremens upon gabapentin withdrawal [letter]. J Clin Psychiatry 2007, 68(3):483-484.
23. Keppra, levetiracetam [product information]. Keppra UCB Pharma, Smyrna (GA); 2010.
24. Topamax, topiramate [product information]. Janssen Ortho, LLC Guraba, Puerto Rico; 2010.
25. Shorvon S.D. Safety of topiramate: adverse events and relationships to dosing. Epilepsia 1996, 37(Suppl 2):S18-S22.
26. Banta J.T., Hoffman K., Budenz D.L., et al. Presumed topiramate-induced bilateral acute angle-closure glaucoma. Am J Ophthalmol 2001, 132(1):112-114.
27. Rhee D.J., Goldberg M.J., Parrish R.K. Bilateral angle-closure glaucoma and ciliary body swelling from topiramate. Arch Ophthalmol 2001, 119(11):1721-1723.
28. Fakhoury T., Murray L., Seger D., et al. Topiramate overdose: clinical and laboratory features. Epilepsy Behav 2002, 3(2):185-189.
29. Gabitril, tiagabine [product information]; 2010.
30. Spiller H.A., Winter M.L., Ryan M., et al. Retrospective evaluation of tiagabine overdose. Clin Toxicol 2005, 43:855-859.
31. Zonegran, zonisamide [product information]. Elan Pharma International Ltd, Eisai Inc, Teaneck (NJ); 2010.
32. Naito H., Itoh N., Matsui N., et al. Monitoring plasma concentrations of zonisamide and clonazepam in an epileptic attempting suicide by an overdose of the drugs. Curr Ther Res 1988, 43:463-467.
33. Lamictal, lamotrigine [product information]. GlaxoSmithKline Research Park Triangle (NC); 2010.
34. Guberman A.H., Besag F.M., Brodie M.J., et al. Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia 1999, 40(7):985-991.
35. Friis M.L., Kristensen O., Boas J., et al. Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol Scand 1993, 87(3):224-227.
36. Pendlebury S.C., Moses D.K., Eadie M.J. Hyponatraemia during oxcarbazepine therapy. Hum Toxicol 1989, 8(5):337-344.
37. Jolliff H.A., Fehrenbacher N., Dart R.C. Bradycardia, hypotension, and tinnitus after accidental oxcarbazepine overdose [abstract]. Clin Toxicol 2001, 39:316-317.